. Author manuscript; available in PMC: 2014 Feb 1.

Published in final edited form as: Am J Geriatr Psychiatry. 2013 Apr 3;22(2):177–185. doi: 10.1016/j.jagp.2012.08.017

TABLE 2.

Effects of ApoE4 Allele, ACE Inhibitor Use, and the Interaction Between ApoE4 Status and ACE Inhibitor Use on Alzheimer Disease

	Model I Alzheimer disease (N = 348)				Model II Alzheimer disease (N = 308)
	Odds Ratio (95% CI)	DF	Wald χ²	p value	Odds Ratio (95% CI)	DF	Wald χ²	p value
Age, years	1.13 (1.08, 1.18)	1	27.39	<0.0001	1.14 (1.09,1.19)	1	27.94	<0.0001
White	0.81 (0.65, 1.02)	1	2.57	0.07	0.79 (0.63, 1.00)	1	2.94	0.05
School, years	0.89 (0.80, 1.00)	1	3.99	0.05	0.88 (0.79, 0.99)	1	4.36	0.04
ApoE4	1.42 (0.66, 3.05)	1	0.49	0.36	0.25 (0.05, 1.21)	1	3.26	0.09
ACE inhibitor use	1.27 (0.64, 2.54)	1	0.54	0.49	0.57 (0.24, 1.38)	1	1.33	0.22
ApoE4*ACE inhibitors	-	-	-	-	20.85 (3.08, 140.95)	1	9.59	0.002

Notes: Using multivariate logistic analysis, we first examined the associations between AD and ApoE4 + ACE inhibitor independently (model I), then the interaction of ApoE4 and the ACE inhibitor use (model II) after adjusting for age, ethnicity, and school. ApoE4*ACE inhibitor: interaction between ApoE4 and ACE inhibitor use. Odds ratios with 95% confidence interval (95% CI), DF, and Wald χ² test were shown for each variable in the models. p values for statistical significance are shown.